# Research Pulse — 2026-09-19 _Generated 2026-09-19 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 19일 (토요일) · Institutionalizing(제도화) Day** 9/19(제도화) → 9/18(산업화) → 9/17(확산) → 9/16(종합) → 9/15(검증) → 9/14(정밀화) → 9/13(가동화) → 9/12(다양화). Industrializing(9/18)된 기술들이 **기관별 내부 규범·표준 운영 절차·규제 집행 체계로 내재화(Institutionalizing) 단계로 이전하며 기술 적용이 기관의 일상적 운영 체계로 녹아드는 날** — Ngo et al.으로 CRISPR in vivo delivery systematic review — AAV·LNP·VLP·SEND 각각의 tissue tropism과 immunogenicity 체계적 분류(Nature Biotechnology 2026), He et al.으로 AstraZeneca ChatInvent multi-agent production deployment — proof-of-concept → multi-agent GUI architecture 산업적 이행(Drug Discovery Today 2026), Crescioli et al.으로 2025년 항체 Therapeutic 19개 승인 + 26개 regulatory review — bispecific ADC izalontamab brengitecan 등 ADC/BsADCs 영역 확장(mAbs 2026), Huang et al.으로 spatial visual proteomics — tumor microenvironment dynamics에서 spatial proteomics가 transcriptomics와 통합 frameworks 확립(Genomics Proteomics Bioinformatics 2026), Lee et al.으로 FDA AI/ML devices 1,430개 authorization longitudinal analysis — radiology 76.5% concentration 감소 추세 + startup/tech company nonradiology authorization 확대(J Med Internet Research 2026), Ji X. et al.으로 BsADCs breast cancer — ZW49·BL-B01D1·JSKN003 Phase III 진입, TNBC 적용 확산(Cancer Chemotherapy Pharmacology 2026)이 동시에 진행된다. Institutionalizing은 Industrializing의 다음 단계다. 오늘 6개 전선은 산업화된 기술들이 **기관의 표준 운영 체계로 내재화되며 Delivery Platform Categorization · AI Agent Production Deployment · Antibody Modality Diversification · Spatial Proteomics Integration · FDA AI/ML Regulatory Governance · ADC/BsADC Clinical Translation**으로 구체적 제도화 단계에 진입하는 날이다. *출처: [Ngo CRISPR In Vivo Delivery Nature Biotechnology 2026](https://consensus.app/papers/details/a3c724f14f3e505b9a768819ca774352/), [He ChatInvent AstraZeneca Drug Discovery Today 2026](https://consensus.app/papers/details/4dc8cd75fd9d59a5943e992c0a05ae28/), [Crescioli Antibodies to Watch 2026 mAbs 2026](https://consensus.app/papers/details/c0e70a5339d55e7e8ff554cb529b122c/), [Huang Spatial Visual Proteomics Genomics Proteomics Bioinformatics 2026](https://consensus.app/papers/details/f1d287c05c5f555da339be95e058525d/), [Lee FDA AI ML Devices J Med Internet Research 2026](https://consensus.app/papers/details/dfad743b83a350c7a75e83750aff6fdf/), [Ji BsADCs Breast Cancer Cancer Chemotherapy Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/)* *#InstitutionalizingDay #Ngo #NatureBiotechnology #CRISPR #InVivoDelivery #AAV #LNP #VLP #SEND #TissueTropism #He #ChatInvent #AstraZeneca #DrugDiscoveryToday #AIAgents #MultiAgent #ProductionDeployment #Crescioli #mAbs #AntibodiesToWatch #BispecificADC #Izalontamab #Huang #SpatialProteomics #TumorMicroenvironment #GenomicsProteomicsBioinformatics #Lee #FDA #AIML #MedicalDevices #Authorization #Radiology #Diversification #Ji #BsADCs #BreastCancer #ZW49 #BLB01D1 #TNBC #Phase3 #Institutionalizing #DeliveryPlatform #Standardization #BiomedicalAI #DailyReport* --- ### Post 2: CRISPR & Gene Editing — In Vivo Delivery Platform Categorization과 Organ-Specific Editing Standardization 🪄 **[CRISPR/Gene Editing] Ngo et al.으로 CRISPR in vivo delivery systematic review — AAV·LNP·VLP·SEND 각각의 tissue tropism·immunogenicity·editing efficiency 체계적 분류, "magic bullet" 이상적 도달 위한 tissue-targeted delivery 전략(Nature Biotechnology 2026) + Xue et al.으로 CRISPR delivery strategies comprehensive review — AAV·VLP·SEND·LNP 각각의 load capacity·specificity·toxicity 체계적 비교(Artificial cells Nanomedicine Biotechnology 2026) + Martin et al.으로 in vivo CRISPR delivery organ-specific strategies — liver·CNS·muscle·eye 각각의 최적 delivery modality와 anatomical/cellular/immunological constraints 종합(Int J Biological Sciences 2026): CRISPR In Vivo Delivery의 Institutionalizing(제도화) 동시 확인** CRISPR 유전자 편집 기술의**in vivo delivery 표준화·플랫폼 분류·기관 내재화(Institutionalizing)**가 출처에서 동시에 확인된다[1][2][3]. **In Vivo Delivery Platform Categorization: AAV·LNP·VLP·SEND 체계적 분류[1]** W. Ngo et al.(Nature Biotechnology 2026)의 review는 CRISPR genome editors의 in vivo delivery를 체계적으로 분석한다. **핵심 프레임워크 — Platform Categorization**: 각각의 tissue tropism, immunogenicity, editing efficiency에 따른 최적 delivery platform 분류. **핵심 성과 1 — AAV**: 높음 tropism + 면역 원성 + 크기 제한(적절한 유전자 크기). **핵심 성과 2 — LNP**: 간 표적 우위 + 면역 원성 낮음 + 반복 투여 가능성. **핵심 성과 3 — VLP**:virus-like particles — 면역 원성 회피 + 크기 유연성. **핵심 성과 4 — SEND**:synthetic nanocarriers — 표적화 유연성. **핵심 성과 5 — "Magic Bullet" 개념**: 정확하고 안전하게 유전 질환을 치료하는 정밀한 도달. **핵심**: CRISPR in vivo delivery platform categorization + tissue-targeted delivery — CRISPR Institutionalizing Consolidating. **CRISPR Delivery Strategies Comprehensive Review: 각 modality 체계적 비교[2]** F.-Y. Xue et al.(Artificial cells, Nanomedicine, and Biotechnology 2026)의 review는 CRISPR delivery strategies를 포괄적으로 비교한다[2]. **Delivery Methods 4가지**: (i) **Biological — AAV**: capsid engineering으로 조직 특이성 확대 가능, (ii) **Biological — VLP**: immunogenicity 회피, (iii) **Biological — SEND**: synthetic envelope components, (iv) **Chemical — LNP**: 간 표적 우위. **핵심 성과 1 — Load capacity**: AAV(적정 크기) vs LNP(큰 cargo) vs VLP(중간). **핵심 성과 2 — Immunogenicity**: AAV(상대적 높음) vs LNP(낮음) vs VLP/SEND(회피 가능). **핵심 성과 3 — Specificity**: 각 플랫폼의 표적화 전략. **핵심 성과 4 — Toxicity profiles**: 안전성 프로파일 비교. **핵심**: CRISPR delivery strategies comprehensive comparison — 기관 내재화를 위한 표준 분류 체계. **Organ-Specific Delivery Strategies: Anatomical/Cellular/Immunological Constraints[3]** L. Martin et al.(Int J Biological Sciences 2026)의 review는 CRISPR systems의 in vivo delivery를 장기별로 분석한다[3]. ** COST Action GenE-HumDi Network 기여**. **핵심 성과 1 — Anatomical constraints**: 각 장기별解剖학적 특성에 따른 전달 전략. **핵심 성과 2 — Cellular constraints**: 세포 수준 uptake와 intracellular trafficking. **핵심 성과 3 — Immunological constraints**: 면역 반응과 immunogenicity 관리. **핵심 성과 4 — Organ-specific strategies**: (i) **Liver**: LNP 우위 — 간 표적화 자연적 경로, (ii) **CNS**: BBB penetration — split-AAV, engineered peptides 필요, (iii) **Muscle**: AAV 우위 — 근육 특이적 tropism, (iv) **Eye**: subretinal injection — 국소 전달 가능. **핵심 성과 5 — Delivery Governs Efficacy/Safety/Scalability**: 전달이 efficacy, safety, scalability의 핵심 결정인자. **핵심**: in vivo CRISPR organ-specific delivery strategies — 장기별 표준 delivery protocol Institutionalizing. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Ji Neuroprotection PE BBB**로 **split-AAV/lipid nanoparticles/engineered peptides 3가지 전략**(Industrializing)을, **Feierman AJHG umbrella trial**으로 **FDA plausible mechanism framework**(Industrializing)를 제시했다면, 오늘은 **Ngo Nature Biotechnology**으로 **CRISPR in vivo delivery platform 체계적 categorization**(Institutionalizing — 플랫폼 표준 분류)을(new angle), **Xue review**로 **각 modality의 load capacity/immunogenicity/specificity/toxicity 체계적 비교**(Institutionalizing — 표준 비교 프레임워크)를(new angle), **Martin**로 **장기별 delivery strategies와 anatomical/cellular/immunological constraints 종합**(Institutionalizing — 표준 protocol 내재화)을 동시에 제시한다. Industrializing(9/18) → CRISPR Institutionalizing(9/19). 실무 함의: 전달 기술팀에서 Ngo et al.의 platform categorization framework를 참조하여 기관별 최적 delivery modality selection strategy를 수립해야 한다. *출처: [Ngo CRISPR In Vivo Delivery Nature Biotechnology 2026](https://consensus.app/papers/details/a3c724f14f3e505b9a768819ca774352/), [Xue CRISPR Delivery Strategies Artificial Cells Nanomedicine Biotechnology 2026](https://consensus.app/papers/details/2b7f53db10d8570891c63e2cf66fa2e0/), [Martin In Vivo CRISPR Delivery Int J Biological Sciences 2026](https://consensus.app/papers/details/5d58355f4ce053dc80e42bf7ba924045/)* *#CRISPR #GeneEditing #InVivoDelivery #Ngo #NatureBiotechnology #MagicBullet #TissueTargeting #PlatformCategorization #AAV #LNP #VLP #SEND #TissueTropism #Immunogenicity #Xue #ArtificialCells #Nanomedicine #Biotechnology #LoadCapacity #Specificity #Toxicity #Martin #IntJBiologicalSciences #GenEHumDi #OrganSpecific #Liver #CNS #Muscle #Eye #Anatomical #Cellular #Immunological #Constraints #InstitutionalizingDay #DeliveryPlatform #Standardization #Protocol #BiomedicalAI #DailyReport* --- ### Post 3: AI 신약 — ChatInvent AstraZeneca Production Deployment와 AI Agent Level 2/3 Autonomy Taxonomy 💊 **[AI 신약] He et al.으로 AstraZeneca ChatInvent production deployment — proof-of-concept single agent → multi-agent GUI architecture → scalable multi-agent architecture 산업적 이행(Drug Discovery Today 2026) + Huynh et al.으로 AI agents drug discovery 6대 기능 comprehensive review — literature synthesis·protocol generation·toxicity prediction·synthesis·repurposing·end-to-end( Drug Discovery Today 2026) + Das et al.으로 AI agents evolution 4 eras · Level 2 collaborative agents mainstream · Level 3 autonomous specialists emerging — Phase I 25-30% success rate improvement · preclinical cost 30-40% reduction (Computer Methods Programs Biomedicine 2026): AI Drug Discovery Institutionalizing(제도화) 동시 확인** AI-Driven Drug Discovery의**실제 산업 배치와 자율성 단계 분류(Institutionalizing)**가 출처에서 동시에 확인된다[4][5][6]. **ChatInvent AstraZeneca Production Deployment: Multi-Agent Architecture 산업적 이행[4]** J. He et al.(Drug Discovery Today 2026)의 연구는 AstraZeneca의 ChatInvent agentic system 실제 배치 사례를 제시한다. **핵심 성과 1 — 산업적 이행里程碑**: AstraZeneca discovery pipeline에 통합 — literature synthesis + molecular design + synthesis planning. **핵심 성과 2 — Multi-agent architecture**: proof-of-concept single agent → extensible multi-agent architecture with GUI. **핵심 성과 3 — Lessons learnt**: real-world adoption의 실제 경험과 도전과제. **핵심 성과 4 — Scalable deployment**: pharmaceutical production 환경에서의 확장 가능성 확인. **핵심 메시지**: AI agent drug discovery의 첫 실제 pharmaceutical production deployment — AI drug discovery Institutionalizing Consolidating. **AI Agents Drug Discovery 6대 기능 Comprehensive Review[5]** D.-L. Huynh et al.(Drug Discovery Today 2026)의 review는 AI agents의 drug discovery 적용을 포괄적으로 분석한다[5]. **6대 적용 분야**: (i) literature synthesis, (ii) automated protocol generation, (iii) toxicity prediction, (iv) small-molecule synthesis, (v) drug repurposing, (vi) end-to-end decision-making. **핵심 성과 1 — Substantial gains**: speed, reproducibility, scalability. **핵심 성과 2 — Challenges**: data heterogeneity, system reliability, privacy, benchmarking. **핵심**: AI agents 6 functionalities comprehensive review — AI drug discovery Institutionalizing Consolidating. **AI Agents Evolution 4 Eras + Level 2/3 Autonomy Taxonomy[6]** S. Das et al.(Computer Methods and Programs in Biomedicine 2026)의 review는 AI agents의 evolution과 자율성 단계를 분석한다[6]. **4 Eras**: (i) 1990-2012: database systems, (ii) 2012-2022: machine learning, (iii) 2022-2023: foundation learning tools, (iv) 2023-present: autonomous agents. **핵심 성과 1 — Level 2 collaborative agents mainstream**: Level 2(협업 에이전트) 현재 주류. **핵심 성과 2 — Level 3 autonomous specialists emerging**: Level 3(자율 전문 에이전트) 특정 영역에서 출현. **핵심 성과 3 — Phase I 25-30% improvement**: industry-disclosed estimate. **핵심 성과 4 — Preclinical cost 30-40% reduction**: industry-disclosed estimate. **핵심 성과 5 — Autonomy-Trust Framework**: 4단계 자율성-신뢰 인프라 매핑. **핵심 성과 6 — AlphaEvolve, AI Co-scientist, DrugAgent, Boltz-1/2, Isomorphic Labs**: 주요 breakthrough systems 분석. **핵심**: AI agents 4 eras evolution + Level 2/3 taxonomy — AI drug discovery Institutionalizing Consolidating. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Lin GEN Biotechnology**으로 **2026년 Eli Lilly/Recursion/Regor/Novartis/AbbVie 대형 Deals**(Industrializing)를, **Liu multi-omics AI**로 **AI drug discovery pipeline 적용**(Industrializing)을 제시했다면, 오늘은 **He AstraZeneca ChatInvent**으로 **실제 pharmaceutical production environment에서의 multi-agent deployment**(Institutionalizing — 산업 내재화里程碑)를(new angle), **Huynh 6 functionalities**로 **AI agents의 포괄적 기능 체계**(Institutionalizing — 표준 기능 분류)를(new angle), **Das Level 2/3 taxonomy**로 **AI agent autonomy 단계 분류 체계**(Institutionalizing — 기관 운영 표준 체계)를 동시에 제시한다. Industrializing(9/18) → AI drug discovery Institutionalizing(9/19). 실무 함의: AI drug discovery 팀에서 Das et al.의 Level 2/3 autonomy framework를 참조하여 기관 내 AI agent deployment strategy를 수립해야 한다. *출처: [He ChatInvent AstraZeneca Drug Discovery Today 2026](https://consensus.app/papers/details/4dc8cd75fd9d59a5943e992c0a05ae28/), [Huynh AI Agents Drug Discovery Drug Discovery Today 2026](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/), [Das AI Agents Evolution Computer Methods Programs Biomedicine 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/)* *#AI #DrugDiscovery #He #ChatInvent #AstraZeneca #DrugDiscoveryToday #ProductionDeployment #MultiAgent #GUI #Huynh #LiteratureSynthesis #ProtocolGeneration #ToxicityPrediction #Synthesis #Repurposing #EndToEnd #Das #ComputerMethods #ProgramsInBiomedicine #AIAgents #Level2 #Level3 #Autonomy #CollaborativeAgents #AutonomousSpecialists #AlphaEvolve #CoScientist #DrugAgent #Boltz #IsomorphicLabs #PhaseI #25To30Percent #PreclinicalCost #30To40Percent #InstitutionalizingDay #ProductionStandardization #AutonomyFramework #BiomedicalAI #DailyReport* --- ### Post 4: 단백질 AI — CRISPR Delivery Platform에 따른 단백질 Engineering 적용과 Delivery-Targetability 상관관계 🔬 **[단백질 AI] CRISPR in vivo delivery platform Categorization(Institutionalizing)과 관련하여 단백질 engineering의 delivery platform별 적용 가능성 분석 — LNP의 liver-specific protein replacement + AAV의 muscle/CNS targeted protein augmentation + VLP/SEND의 customized tissue targeting + Martin et al.의 organ-specific delivery strategies 체계화(Int J Biological Sciences 2026): 단백질 AI와 Delivery Platform Integration Institutionalizing 동시 확인** 단백질 AI의**in vivo delivery 플랫폼 분류 체계와 장기별 적용 전략 통합(Institutionalizing)**이 출처에서 동시에 확인된다[3]. **Delivery Platform-Linked Protein Engineering Applications[3]** L. Martin et al.(Int J Biological Sciences 2026)의 review는 CRISPR systems의 in vivo delivery를 장기별로 분석하며 단백질 engineering과의 통합을 논의한다[3]. **Liver**: LNP-based delivery — 간 표적 단백질 치환/보강. **CNS**: BBB penetration 필요 — split-AAV, engineered peptides — 신경퇴행성 질환 단백질 보강. **Muscle**: AAV-based — 근육 특이적 단백질 augmentation — Duchenne muscular dystrophy 등. **Eye**: 국소 주사 — subretinal injection — 유전성 안구 질환 단백질 치환. **핵심 메시지**: delivery platform 선택이 단백질 engineering 적용 가능성을 결정 — Institutionalizing Consolidating. **Institutionalizing 관점에서의 단백질 AI:** CRISPR delivery platforms의 표준화가 단백질 engineering의 기관 내재화와 직결. Delivery platform categorization이 단백질 치료제의 조직 표적화를 위한 표준 operating procedure로 기능. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Singh AlphaFold-ligand data gap**으로 **단백질 AI drug discovery 적용 한계**(Industrializing)를, **Kinde AlphaFold vaccine design**으로 **단백질 AI vaccine 적용**(Industrializing)을 제시했다면, 오늘은 **Martin organ-specific delivery**를 **단백질 AI + delivery platform integration Institutionalizing 관점**으로 재해석하여(delivery platform이 단백질 engineering 적용 결정), **Ngo categorization**과 연결하여 institutionalizing framework를 제시한다. Industrializing(9/18) → 단백질 AI Institutionalizing(9/19). 실무 함의: 단백질 치료제 개발팀에서 Martin et al.의 organ-specific delivery strategies를 참조하여 protein replacement/augmentation strategy를 수립해야 한다. *출처: [Martin In Vivo CRISPR Delivery Int J Biological Sciences 2026](https://consensus.app/papers/details/5d58355f4ce053dc80e42bf7ba924045/), [Ngo CRISPR In Vivo Delivery Nature Biotechnology 2026](https://consensus.app/papers/details/a3c724f14f3e505b9a768819ca774352/)* *#ProteinAI #CRISPR #DeliveryPlatform #Institutionalizing #Martin #IntJBiologicalSciences #OrganSpecific #Liver #CNS #Muscle #Eye #LNP #AAV #VLP #SEND #ProteinEngineering #ProteinReplacement #Augmentation #TissueTargeting #BBB #Ngo #NatureBiotechnology #PlatformCategorization #MagicBullet #Standardization #InstitutionalizingDay #Protocol #SOP #BiomedicalAI #DailyReport* --- ### Post 5: FDA/규제 — Antibodies to Watch 2026과 ADC/BsADC Modalities Institutionalizing 🏛️ **[FDA/규제] Crescioli et al.으로 2025년 항체 therapeutics 19개 first approvals + 26개 regulatory review — izalontamab brengitecan bispecific ADC 포함, 209개 late-stage pipeline预测, non-cancer 76%(mAbs 2026) + Strohl et al.으로 2025년 FDA 10개 therapeutic antibody molecules 승인 — ADC 2개, TCE bispecific 1개, Fc-modified 2개, FcRn 1개, hyaluronidase co-formulation 2개, antibody-like scaffold-fusion protein 1개(Antibody Therapeutics 2026) + Lee et al.으로 FDA AI/ML devices 1,430개 authorization longitudinal — 2025년 331개, radiology 76.5%→77.5%→현재 76.5%, diversification 추세, startup/tech company nonradiology 확대(J Med Internet Research 2026): FDA/규제 Institutionalizing(제도화) 동시 확인** FDA/규제의**항체 modality 다양화와 AI/ML device governance 체계화(Institutionalizing)**가 출처에서 동시에 확인된다[7][8][9]. **Antibodies to Watch 2026: 19 Approvals + 26 Regulatory Review + ADC Expansion[7]** S. Crescioli et al.(mAbs 2026)의 annual review는 2026년 항체 therapeutics 현황을 분석한다[7]. **2025 First approvals**: 19개 항체 치료제 최초 승인. **Regulatory review**: 26개 molecules — bispecific ADC izalontamab brengitecan 포함. **Late-stage pipeline**: 209개 commercial late-stage molecules. **Prediction 2026**: 21개 molecules regulatory review 진입 예상. **Modality distribution**: non-cancer indications 76% (16/21), conventional format 62% (13/21). **ADC/BsADC pipeline**: delpacibart etedesiran, delpacibart zotadirsen, zeleciment rostadirsen, sonesitatug vedotin, trastuzumab pamirtecan, ifinatamab deruxtecan — 다수의 antibody-drug/orligo conjugates. **Bispecific**: petosemtamab. **China approvals**: China-originated antibody therapeutics 승인 증가 추세. **Development timeline**: 평균 ~6년 (임상 개발 + 규제 검토). **핵심**: Antibodies to Watch 2026 — ADC/BsADC modality expansion + non-cancer pipeline growth — FDA/규제 Institutionalizing Consolidating. **2025 FDA Therapeutic Antibody Approvals: 10개 Molecules + Modality Diversification[8]** W.R. Strohl(Antibody Therapeutics 2026)의 분석은 2025년 FDA 승인된 10개 therapeutic antibody molecules를 분석한다[8]. **2025 approvals**: 총 44개 NME 중 10개 항체 기반分了. **Modality breakdown**: (i) ADC 2개, (ii) TCE bispecific antibody 1개, (iii) Fc-modified half-life extended antibodies 2개, (iv) complex coagulation pathway targeting 2개, (v) 8번째 novel anti-PD-1 antibody 1개, (vi) FcRn targeting biologics 1개, (vii) hyaluronidase co-formulation (rapid SC dosing) 2개, (viii) antibody-like scaffold-fusion protein 1개 ( впер). **ADC approvals**: 2개 ADC 승인. **Bispecific TCE**: 1개 T-cell engager bispecific 승인. **New modality entries**: antibody-like scaffold-fusion protein (신규 modality). **핵심**: 2025 FDA antibody therapeutics approvals — modality diversification + new scaffold entries — FDA Institutionalizing Consolidating. **FDA AI/ML Medical Devices: 1,430개 Authorization Longitudinal + Diversification[9]** Y.-S. Lee et al.(J Med Internet Research 2026)의 연구는 FDA AI/ML-enabled medical devices의 30년 longitudinal analysis를 수행한다[9]. **Annual authorizations**: Era 1(1995-2015) 평균 2.0개/년 → Era 4(2023-2025) 평균 264개/년. **2025 alone**: 331개 authorization. **Radiology concentration**: 76.5% (1,094/1,430 cumulative) — Era 3 peak 85.5% → Era 4 77.5%로 감소. **Diversification**: HHI 0.738(Era 3) → 0.612(Era 4) — 통계적으로 유의미한 다양화. **Startup vs incumbent**: startup OR 5.09, technology company OR 50.62 — nonradiology authorization 확대로/startup/tech company 참여 확대. **510(k) pathway**: 96.2% (1,376/1,430). **Clinical specialties diversification**: Era 4에서 radiology 외 specialties 확대. **핵심**: FDA AI/ML devices 30년 longitudinal — radiology concentration 감소 + nonradiology authorization 확대 + startup/tech company 참여 증가 — FDA Institutionalizing Consolidating. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Feierman AJHG**으로 **FDA plausible mechanism framework**(Industrializing)를, **Lin Deals**으로 **빅파마 AI investments**(Industrializing)를 제시했다면, 오늘은 **Crescioli mAbs**으로 **2026 antibody therapeutics pipeline — ADC/BsADC expansion + non-cancer 76%**(Institutionalizing — modality standardization)을(new angle), **Strohl**으로 **2025 FDA 10개 antibody approvals — new scaffold/fusion protein modality**(Institutionalizing — regulatory framework expansion)를(new angle), **Lee**으로 **FDA AI/ML 30년 longitudinal — radiology concentration 감소 + diversification**(Institutionalizing — governance standardization)을 동시에 제시한다. Industrializing(9/18) → FDA/규제 Institutionalizing(9/19). 실무 함의: 규제 기획팀에서 Crescioli et al.의 antibody therapeutics pipeline analysis를 참조하여 antibody modality investment strategy를 수립해야 한다. *출처: [Crescioli Antibodies to Watch 2026 mAbs 2026](https://consensus.app/papers/details/c0e70a5339d55e7e8ff554cb529b122c/), [Strohl FDA Therapeutic Antibodies 2025 Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/), [Lee FDA AI ML Devices J Med Internet Research 2026](https://consensus.app/papers/details/dfad743b83a350c7a75e83750aff6fdf/)* *#FDA #Regulation #Antibodies #Therapeutics #Crescioli #mAbs #AntibodiesToWatch #2026 #19Approvals #26RegulatoryReview #BispecificADC #Izalontamab #ADC #BsADC #209Pipeline #NonCancer #76Percent #Strohl #AntibodyTherapeutics #2025 #10Approvals #ADC2 #TCEBispecific #FcModified #Hyaluronidase #ScaffoldFusionProtein #Lee #JMedInternetResearch #AIML #MedicalDevices #1430 #Longitudinal #331 #2025 #Radiology #76Point5Percent #Diversification #HHI #Startup #TechCompany #Nonradiology #Authorization #InstitutionalizingDay #ModalityDiversification #Governance #Standardization #BiomedicalAI #DailyReport* --- ### Post 6: Single-Cell Multi-Omics Foundation Model — AI Agent Integration과 Level 2/3 Autonomy Framework 🧫 **[Single-Cell Multi-Omics] Das et al.으로 AI agents drug discovery Level 2 collaborative agents mainstream + Level 3 autonomous specialists emerging — Level 2: 인간 협업으로 반복적 작업 자동화, Level 3: 특정 영역 자율적 전문 판단 + Autonomy-Trust Framework 4단계(Computer Methods Programs Biomedicine 2026) + He et al.으로 AstraZeneca ChatInvent multi-agent deployment — molecular design + synthesis planning + literature synthesis 통합( Drug Discovery Today 2026): Single-Cell AI Agent Institutionalizing(제도화) 동시 확인** Single-Cell Multi-Omics의**AI Agent Integration과 Autonomy Framework 적용(Institutionalizing)**이 출처에서 동시에 확인된다[6][4]. **Level 2/3 Autonomy Framework: Drug Discovery Application[6]** S. Das et al.(Computer Methods and Programs in Biomedicine 2026)의 review는 AI agents의 자율성 단계를 분석한다[6]. **Level 2 — Collaborative Agents**: 인간 협업으로 반복적 작업 자동화 — single-cell data 분석, QC filtering, annotation 보조. **Level 3 — Autonomous Specialists**: 특정 영역에서 자율적 전문 판단 — single-cell foundation model fine-tuning, perturbation prediction. **Autonomy-Trust Framework 4단계**: 각 Level별 trust infrastructure와 validation strategy 매핑. **+Masking +LLMEval**: Level 2/3 validation 도구. **핵심**: AI agent Level 2/3 taxonomy — single-cell analysis Institutionalizing Consolidating. **ChatInvent Multi-Agent Integration: Molecular Design + Synthesis Planning[4]** J. He et al.(Drug Discovery Today 2026)의 AstraZeneca 사례는 multi-agent system의 통합을 보인다[4]. **Integration domains**: molecular design + synthesis planning + literature synthesis. **실제 pharmaceutical pipeline 적용**: discovery workflow 내 multiple stages에 agentic system 통합. **핵심**: ChatInvent multi-agent integration — single-cell analysis Institutionalizing Consolidating. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Boya Ji CAPTAIN**으로 **scRNA + protein 382 multimodal integration**(Industrializing)을, **Wang HiC-Foundation**으로 **3D genome FM**(Industrializing)을 제시했다면, 오늘은 **Das Level 2/3 taxonomy**를 **Institutionalizing 관점에서 재해석**하여(single-cell analysis workflow의 표준 운영 체계 내재화), **He ChatInvent**을 **multi-agent integration Institutionalizing**으로 재제시한다. Industrializing(9/18) → Single-Cell Institutionalizing(9/19). 실무 함의: Single-cell 분석팀에서 Das et al.의 Level 2/3 framework를 참조하여 기관 내 AI agent integration strategy를 수립해야 한다. *출처: [Das AI Agents Evolution Computer Methods Programs Biomedicine 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/), [He ChatInvent Drug Discovery Today 2026](https://consensus.app/papers/details/4dc8cd75fd9d59a5943e992c0a05ae28/)* *#SingleCell #MultiOmics #FoundationModel #AIAgents #Institutionalizing #Das #ComputerMethods #ProgramsInBiomedicine #Level2 #Level3 #Autonomy #CollaborativeAgents #AutonomousSpecialists #AutonomyTrustFramework #He #ChatInvent #AstraZeneca #MultiAgent #MolecularDesign #SynthesisPlanning #LiteratureSynthesis #Integration #Standardization #Protocol #BiomedicalAI #DailyReport* --- ### Post 7: Spatial Transcriptomics/Cancer Atlas — Spatial Visual Proteomics Integration과 ADC/BsADC TME Targeting 🗺️ **[Spatial Transcriptomics/Cancer Atlas] Huang et al.으로 spatial visual proteomics — tumor microenvironment dynamics에서 spatial proteomics가 imaging mass cytometry·multiplex fluorescence·tissue expansion microscopy로 transcriptomics와 통합 frameworks 확립(Genomics Proteomics Bioinformatics 2026) + Ji X. et al.으로 BsADCs breast cancer — ZW49 biparatopic HER2·BL-B01D1 EGFR×HER3·JSKN003 TROP2×HER3 Phase III 진입, TNBC 적용 확산(Cancer Chemotherapy Pharmacology 2026) + Nguyen et al.으로 spatial omics TME profiling — ST+SP 통합 + AI/ML cross-platform integration(Clinical Translational Immunology 2026): Spatial Transcriptomics Institutionalizing(제도화) 동시 확인** Spatial Transcriptomics/Cancer Atlas의**spatial proteomics 통합과 ADC/BsADC 임상 적용(Institutionalizing)**이 출처에서 동시에 확인된다[10][11][12]. **Spatial Visual Proteomics: Tumor Microenvironment Dynamics + Multi-Modal Integration[10]** P. Huang et al.(Genomics, Proteomics & Bioinformatics 2026)의 review는 spatial visual proteomics의 tumor microenvironment 적용을 분석한다[10]. **핵심 성과 1 — Laser capture microdissection**: 정밀 세포 분할. **핵심 성과 2 — Antibody-based platforms**: multiplexed proteomic profiling. **핵심 성과 3 — Tissue expansion microscopy**: 해상도 향상. **핵심 성과 4 — Chemical biology-based probes**: 세포 유형 특이적 proteome profiling. **핵심 성과 5 — Computational tools**: cell segmentation, data deconvolution, multi-omics integration. **핵심 성과 6 — Applications**: tumor heterogeneity, stromal-immune interactions, metabolic reprogramming. **핵심 성과 7 — Immune evasion + therapeutic resistance**: 공간적 관점에서의 면역 회피 메커니즘. **핵심**: spatial visual proteomics — spatial proteomics Institutionalizing Consolidating. **BsADCs Breast Cancer: Phase III Trials + TNBC Application Expansion[11]** X. Ji et al.(Cancer Chemotherapy and Pharmacology 2026)의 review는 BsADCs의 유방암 적용을 분석한다[11]. **핵심 성과 1 — ZW49 biparatopic HER2**: receptor clustering + robust internalization. **핵심 성과 2 — BL-B01D1 EGFR×HER3**: compensatory pathway targeting — TNBC에서 breakthrough efficacy. **핵심 성과 3 — JSKN003 TROP2×HER3**: dual targeting strategy. **핵심 성과 4 — Phase III trials**: 다수의 BsADCs Phase III 진입. **핵심 성과 5 — Linker technology + DAR optimization**: 안정성 개선 + 치료 창 확대. **핵심 성과 6 — TNBC 적용**: triple-negative breast cancer에서 효과 확인. **핵심**: BsADCs Phase III 진입 + TNBC 적용 확산 — ADC/BsADC Institutionalizing Consolidating. **Spatial Omics TME Profiling: ST+SP Integration + AI/ML[12]** H. Nguyen et al.(Clinical & Translational Immunology 2026)의 review는 spatial omics의 TME profiling을 종합한다[12]. **핵심 성과 1 — Spatial transcriptomics + spatial proteomics 통합**: ST+SP combination. **핵심 성과 2 — AI/ML integration**: cross-platform integration + computational pipelines. **핵심 성과 3 — Precision cancer medicine 적용**: 암精准医学 적용 확대. **Challenges**: cross-platform integration, data standardization, computational scalability. **핵심**: spatial omics ST+SP integration — spatial Institutionalizing Consolidating. **9월 18일 Industrializing vs 오늘의 차별점**: 9/18이 **Li 12 cancer 56 LCPs**로 **spatial transcriptomics Pan-Cancer atlas**(Industrializing)를, **Nguyen ST+SP integration**으로 **spatial omics TME review**(Industrializing)를 제시했다면, 오늘은 **Huang spatial proteomics**로 **imaging mass cytometry + tissue expansion microscopy + chemical probes 체계적 통합**(Institutionalizing — proteomics-specific modality expansion)을(new angle), **Ji BsADCs Phase III**로 **ZW49/BL-B01D1/JSKN003 Phase III 진입 + TNBC 적용**(Institutionalizing — 임상 적용 표준화)을(new angle), **Nguyen ST+SP**를 **Institutionalizing 관점에서 재해석**한다. Industrializing(9/18) → Spatial Transcriptomics Institutionalizing(9/19). 실무 함의: 암면역 치료팀에서 Ji et al.의 BsADCs Phase III results를 참조하여 ADC/BsADC clinical trial strategy를 수립해야 한다. *출처: [Huang Spatial Visual Proteomics Genomics Proteomics Bioinformatics 2026](https://consensus.app/papers/details/f1d287c05c5f555da339be95e058525d/), [Ji BsADCs Breast Cancer Cancer Chemotherapy Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/), [Nguyen Spatial Omics TME Clinical Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)* *#SpatialTranscriptomics #CancerAtlas #SpatialProteomics #Institutionalizing #Huang #GenomicsProteomicsBioinformatics #TumorMicroenvironment #ImagingMassCytometry #MultiplexFluorescence #TissueExpansionMicroscopy #ChemicalProbes #CellSegmentation #MultiOmicsIntegration #Ji #CancerChemotherapyPharmacology #BsADCs #BreastCancer #ZW49 #BLB01D1 #JSKN003 #TNBC #Phase3 #Biparatopic #HER2 #EGFR #TROP2 #LinkerTechnology #DAR #Nguyen #ClinicalTranslationalImmunology #SpatialOmics #ST #SP #Integration #AI #ML #PrecisionCancer #InstitutionalizingDay #Standardization #Protocol #ADC #BiomedicalAI #DailyReport* --- ### Post 8: 오늘의 요약 — Institutionalizing(제도화) Day 핵심 정리 🧬 **Institutionalizing(제도화) Day — 9월 19일 핵심 정리** 오늘 Institutionalizing Day의 핵심 메시지 3가지: **1. CRISPR In Vivo Delivery Platform Categorization: 기관 표준 분류 체계 확립** Ngo et al.(Nature Biotechnology 2026)으로 AAV·LNP·VLP·SEND 각각의 tissue tropism·immunogenicity·editing efficiency 체계적 분류[1]. Xue et al.(Artificial cells/Nanomedicine/Biotechnology)로 delivery strategies comprehensive comparison — load capacity/specificity/toxicity 비교[2]. Martin et al.(Int J Biological Sciences 2026)으로 장기별 delivery strategies — liver(CNS/muscle/eye) anatomical/cellular/immunological constraints 종합[3]. CRISPR Institutionalizing — **기관 내 표준 platform categorization + delivery protocol 내재화**. **2. AI Agents Production Deployment + Level 2/3 Autonomy Framework: 산업 운영 체계 내재화** He et al.(Drug Discovery Today 2026)으로 AstraZeneca ChatInvent multi-agent production deployment[4]. Huynh et al.(Drug Discovery Today 2026)으로 AI agents drug discovery 6 functionalities comprehensive review[5]. Das et al.(Computer Methods Programs Biomedicine 2026)으로 AI agents 4 eras evolution + Level 2 collaborative agents mainstream + Level 3 autonomous specialists emerging[6]. AI drug discovery Institutionalizing — **실제 pharmaceutical production deployment + autonomy taxonomy로 기관 운영 표준 체계 내재화**. **3. Antibody Therapeutics Modality Diversification + FDA AI/ML Governance Standardization** Crescioli et al.(mAbs 2026)으로 2025년 19개 approvals + 26개 regulatory review + ADC/BsADC pipeline expansion[7]. Strohl(Antibody Therapeutics 2026)으로 2025년 FDA 10개 antibody approvals + ADC 2개 + TCE bispecific 1개 + new scaffold-fusion protein[8]. Lee et al.(J Med Internet Research 2026)으로 FDA AI/ML devices 1,430개 authorization — radiology 76.5% concentration 감소 + startup/tech company nonradiology 확대[9]. FDA/규제 Institutionalizing — **antibody modality standardization + AI/ML device governance 내재화**. **핵심 인사이트:** Industrializing(9/18)에서 확인된 산업 생태계 형성들이 오늘 **기관의 표준 운영 체계로 내재화(Institutionalizing)**되고 있다. CRISPR delivery는 AAV·LNP·VLP·SEND 플랫폼 표준 분류 체계로, AI agents는 Level 2/3 autonomy framework로, antibody therapeutics는 ADC/BsADC modality standardization으로, FDA AI/ML devices는 nonradiology diversification governance로 각 각 **기관의 일상적 운영 체계**로 전환되고 있다. *출처: [Ngo Nature Biotechnology](https://consensus.app/papers/details/a3c724f14f3e505b9a768819ca774352/) · [Xue Artificial Cells](https://consensus.app/papers/details/2b7f53db10d8570891c63e2cf66fa2e0/) · [Martin Int J Biological Sciences](https://consensus.app/papers/details/5d58355f4ce053dc80e42bf7ba924045/) · [He Drug Discovery Today](https://consensus.app/papers/details/4dc8cd75fd9d59a5943e992c0a05ae28/) · [Huynh Drug Discovery Today](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/) · [Das Computer Methods](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/) · [Crescioli mAbs](https://consensus.app/papers/details/c0e70a5339d55e7e8ff554cb529b122c/) · [Strohl Antibody Therapeutics](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/) · [Lee J Med Internet Research](https://consensus.app/papers/details/dfad743b83a350c7a75e83750aff6fdf/) · [Huang Genomics Proteomics Bioinformatics](https://consensus.app/papers/details/f1d287c05c5f555da339be95e058525d/) · [Ji Cancer Chemotherapy Pharmacology](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/) · [Nguyen Clinical Translational Immunology](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)* *#InstitutionalizingDay #Institutionalizing #Summary #Ngo #NatureBiotechnology #CRISPR #InVivoDelivery #AAV #LNP #VLP #SEND #PlatformCategorization #Xue #ArtificialCells #Nanomedicine #Biotechnology #Martin #IntJBiologicalSciences #OrganSpecific #He #ChatInvent #AstraZeneca #ProductionDeployment #MultiAgent #Huynh #LiteratureSynthesis #ProtocolGeneration #ToxicityPrediction #Das #ComputerMethods #ProgramsInBiomedicine #Level2 #Level3 #Autonomy #CollaborativeAgents #AutonomousSpecialists #Crescioli #mAbs #AntibodiesToWatch #Strohl #AntibodyTherapeutics #ADC #BsADC #TCEBispecific #Lee #JMedInternetResearch #AIML #MedicalDevices #Diversification #Radiology #Huang #SpatialProteomics #TumorMicroenvironment #Ji #BsADCs #BreastCancer #TNBC #ZW49 #BLB01D1 #JSKN003 #Nguyen #SpatialOmics #ST #SP #Integration #Institutionalizing #Standardization #Protocol #SOP #BiomedicalAI #DailyReport* --- ## Sources (1차 출처, 10개 이상 URL) [1] [Ngo et al. — Targeted Delivery of Genome Editors in vivo. Nature Biotechnology 2026](https://consensus.app/papers/details/a3c724f14f3e505b9a768819ca774352/) [2] [Xue et al. — Recent advances of CRISPR-based gene editing technologies and delivery strategies. Artificial cells, Nanomedicine, and Biotechnology 2026](https://consensus.app/papers/details/2b7f53db10d8570891c63e2cf66fa2e0/) [3] [Martin et al. — In vivo delivery strategies for therapeutic CRISPR genome editing. Int J Biological Sciences 2026](https://consensus.app/papers/details/5d58355f4ce053dc80e42bf7ba924045/) [4] [He et al. — Democratising real-world drug discovery through agentic AI. Drug Discovery Today 2026](https://consensus.app/papers/details/4dc8cd75fd9d59a5943e992c0a05ae28/) [5] [Huynh et al. — AI agents in drug discovery: applications and case studies. Drug Discovery Today 2026](https://consensus.app/papers/details/d47b0cf47a4f5055a7175a6fe09bb6e4/) [6] [Das et al. — AI agents in drug discovery: A review of evolution, applications, and future directions. Computer Methods and Programs in Biomedicine 2026](https://consensus.app/papers/details/050c821045db50f495384c9721ee6315/) [7] [Crescioli et al. — Antibodies to watch in 2026. mAbs 2026](https://consensus.app/papers/details/c0e70a5339d55e7e8ff554cb529b122c/) [8] [Strohl — Structure and function of therapeutic antibodies approved by the US FDA in 2025. Antibody Therapeutics 2026](https://consensus.app/papers/details/c1a926c5da6f519d916dced42a5bf0d6/) [9] [Lee et al. — Clinical Specialty Expansion of AI-Enabled and Machine Learning–Enabled Medical Devices Authorized by the US FDA From 1995 to 2025. J Med Internet Research 2026](https://consensus.app/papers/details/dfad743b83a350c7a75e83750aff6fdf/) [10] [Huang et al. — Spatial Visual Proteomics: Insights into Tumor Microenvironment Dynamics. Genomics, Proteomics & Bioinformatics 2026](https://consensus.app/papers/details/f1d287c05c5f555da339be95e058525d/) [11] [Ji et al. — Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemotherapy and Pharmacology 2026](https://consensus.app/papers/details/0323de11ee25558382776e5c8548b117/) [12] [Nguyen et al. — Spatial omics for profiling the dynamic tumor microenvironment. Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/)
Research Pulse·2026-09-19
Research Pulse — 2026-09-19
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief